

Pharmaceutical Products Containing Cannabinoids

What You Should Know?


The International Narcotics Control Board (INCB) has warned about the risks of pharmaceutical products containing cannabinoids, and the dangers of legalising cannabis for recreational use.



Singapore adopts a zero-tolerance stance against illicit drugs, including cannabis. Cannabis is harmful, addictive and there is no scientific evidence on the safety and efficacy of cannabis use.



Cannabis use has **adverse impact on public health**. Effects of short-term use include intoxication and panic attacks, while long-term use is associated with dependence, stroke and increased risk of cancer.



Cannabinoids should only be approved for medical use on the basis of **scientific evidence**.



Clinical trials suggest that while some cannabinoids may relieve the symptoms of certain illnesses, they **do not address the underlying diseases**.



Attempts to market and promote the medical use of cannabis products as “herbal medicines” are **inconsistent with the classification of cannabis** and its derivatives under the 1961 and 1971 conventions.



The legalisation of cannabis use **contravenes international drug control treaties**.

